Myriad invests in Crescendo; takes option to buy company; option exercised
Myriad Genetics Inc. has made a $25mm debt investment in fellow molecular diagnostics company Crescendo Bioscience Inc., and has signed a definitive three-year option agreement to acquire the company.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.